Monday, December 23, 2024
HomeTagsPhase 2 IDEAL Study

Phase 2 IDEAL Study

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

Protagonist Therapeutics announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC). Also Read: Glass Lewis Proxy...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics